Back to Search
Start Over
Early and delayed tranilast treatment reduces pathological fibrosis following myocardial infarction.
- Source :
-
Heart, lung & circulation [Heart Lung Circ] 2013 Feb; Vol. 22 (2), pp. 122-32. Date of Electronic Publication: 2012 Sep 15. - Publication Year :
- 2013
-
Abstract
- Background: Tranilast has been shown to inhibit TGFβ1-related fibrosis and organ failure in various disease models. We sought to examine the effects of tranilast on left ventricular (LV) remodelling post-MI.<br />Methods: Following coronary artery ligation, Sprague Dawley rats were randomised to receive tranilast (300mg/kg/d, p.o.) or vehicle control over one of two treatment periods: (1) from 24h until seven days post-MI, (2) from seven days to 28 days post-MI. Cardiac tissue was harvested for molecular, immunohistochemical and cell culture analyses.<br />Results: Tranilast treatment of MI rats from 24h until seven days post-MI reduced myocardial collagen content, α1 (I) procollagen, TGFβ1 and CTGF mRNA transcripts, monocyte/macrophage infiltration and exacerbated infarct expansion compared with vehicle-treatment. Delaying the commencement of tranilast treatment to seven days post-MI attenuated myocardial fibrosis, gene expression of α1(I) procollagen, α1(III) procollagen, fibronectin, TGFβ1 and CTGF mRNA transcripts, and monocyte/macrophage infiltration at 28d compared to vehicle-treatment, without detriment to infarct healing. Extended post-MI also preserved LV infarct size. In cultures of rat cardiac fibroblasts, tranilast attenuated TGFβ1-stimulated fibrogenesis.<br />Conclusion: Tranilast inhibits myocardial TGFβ1 expression, fibrosis in rat post-MI and collagen production in cardiac fibroblasts. While tranilast intervention from 24h post-MI exacerbated infarct expansion, delaying the commencement of treatment to seven days post-MI impeded LV remodelling.<br /> (Copyright © 2012 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.)
- Subjects :
- Animals
Anti-Inflammatory Agents, Non-Steroidal pharmacology
Cell Count
Cell Proliferation drug effects
Cells, Cultured
Collagen analysis
Collagen biosynthesis
Collagen Type I genetics
Collagen Type I, alpha 1 Chain
Connective Tissue Growth Factor genetics
Coronary Vessels
Fibroblasts drug effects
Fibroblasts metabolism
Fibrosis metabolism
Fibrosis pathology
Fibrosis prevention & control
Ligation
Macrophages
Male
Monocytes
Myocardial Infarction metabolism
Myocardial Infarction pathology
Myocardium chemistry
Organ Size
Phosphorylation
RNA, Messenger
Rats
Rats, Sprague-Dawley
Smad2 Protein metabolism
Smad3 Protein metabolism
Transforming Growth Factor beta1 genetics
Transforming Growth Factor beta1 pharmacology
ortho-Aminobenzoates pharmacology
Anti-Inflammatory Agents, Non-Steroidal therapeutic use
Gene Expression drug effects
Myocardial Infarction drug therapy
Myocardium pathology
Transforming Growth Factor beta1 antagonists & inhibitors
Ventricular Remodeling drug effects
ortho-Aminobenzoates therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1444-2892
- Volume :
- 22
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Heart, lung & circulation
- Publication Type :
- Academic Journal
- Accession number :
- 22986349
- Full Text :
- https://doi.org/10.1016/j.hlc.2012.08.054